Inovio Pharmaceuticals Valuation
| INO Stock | USD 4.19 0.18 4.49% |
At this time, the firm appears to be overvalued. Inovio Pharmaceuticals retains a regular Real Value of $2.52 per share. The prevalent price of the firm is $4.19. Our model calculates the value of Inovio Pharmaceuticals from evaluating the firm fundamentals such as Shares Outstanding of 26.1 M, return on asset of -0.4, and Return On Equity of -0.91 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Inovio Pharmaceuticals' valuation include:
Price Book 1.4232 | Enterprise Value 37 M | Enterprise Value Ebitda (1.09) | Price Sales 184.7724 | Enterprise Value Revenue 158.7978 |
Overvalued
Today
Please note that Inovio Pharmaceuticals' price fluctuation is risky at this time. Calculation of the real value of Inovio Pharmaceuticals is based on 3 months time horizon. Increasing Inovio Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Inovio Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Inovio Stock. However, Inovio Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.19 | Real 2.52 | Target 1.25 | Hype 3.69 |
The intrinsic value of Inovio Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Inovio Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Inovio Pharmaceuticals helps investors to forecast how Inovio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Inovio Pharmaceuticals more accurately as focusing exclusively on Inovio Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Inovio Pharmaceuticals' intrinsic value based on its ongoing forecasts of Inovio Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Inovio Pharmaceuticals' closest peers.
Inovio Pharmaceuticals Cash |
|
Inovio Valuation Trend
Knowing Inovio Pharmaceuticals' actual value is paramount for traders when making sound investment determinations. Using both Inovio Pharmaceuticals' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Inovio Pharmaceuticals Total Value Analysis
Inovio Pharmaceuticals is currently estimated to have company total value of 37 M with market capitalization of 109.36 M, debt of 30.21 M, and cash on hands of 348.13 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Inovio Pharmaceuticals fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
37 M | 109.36 M | 30.21 M | 348.13 M |
Inovio Pharmaceuticals Investor Information
About 34.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.42. Some equities with similar Price to Book (P/B) outperform the market in the long run. Inovio Pharmaceuticals recorded a loss per share of 4.63. The entity had not issued any dividends in recent years. The firm had 1:12 split on the 25th of January 2024. Based on the key indicators related to Inovio Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Inovio Pharmaceuticals may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Inovio Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Inovio Pharmaceuticals has an asset utilization ratio of 0.48 percent. This suggests that the Company is making $0.004811 for each dollar of assets. An increasing asset utilization means that Inovio Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Inovio Pharmaceuticals Ownership Allocation
Inovio Pharmaceuticals has a total of 26.1 Million outstanding shares. 30% of Inovio Pharmaceuticals outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Inovio Pharmaceuticals Profitability Analysis
The company reported the last year's revenue of 832.01 K. Reported Net Loss for the year was (135.12 M) with loss before taxes, overhead, and interest of (177.39 M).About Inovio Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Inovio Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Inovio Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Inovio Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Inovio Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Inovio Pharmaceuticals. We calculate exposure to Inovio Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Inovio Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -2.7 M | -2.5 M | |
| Pretax Profit Margin | (162.40) | (154.28) | |
| Operating Profit Margin | (162.53) | (154.40) | |
| Net Loss | (162.40) | (154.28) | |
| Gross Profit Margin | (3.21) | (3.37) |
Inovio Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 22.2 M |
Inovio Pharmaceuticals Current Valuation Indicators
Inovio Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Inovio Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Inovio Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Inovio Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Inovio Pharmaceuticals' worth.When determining whether Inovio Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inovio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inovio Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inovio Pharmaceuticals Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.63) | Revenue Per Share 0.025 | Quarterly Revenue Growth (0.55) | Return On Assets (0.40) | Return On Equity (0.91) |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.